Neuburgh Advisers LLC grew its holdings in Syneos Health Inc (NASDAQ:SYNH) by 21.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,968 shares of the company’s stock after acquiring an additional 1,040 shares during the quarter. Neuburgh Advisers LLC’s holdings in Syneos Health were worth $305,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Financial Gravity Wealth Inc. acquired a new stake in shares of Syneos Health during the second quarter worth about $29,000. AlphaOne Investment Services LLC increased its position in shares of Syneos Health by 29.0% in the first quarter. AlphaOne Investment Services LLC now owns 1,590 shares of the company’s stock valued at $82,000 after buying an additional 357 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Syneos Health by 83.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 3,314 shares of the company’s stock valued at $170,000 after buying an additional 1,510 shares in the last quarter. Tiverton Asset Management LLC purchased a new stake in shares of Syneos Health in the second quarter valued at approximately $279,000. Finally, Smith Asset Management Group LP increased its position in shares of Syneos Health by 1,039.3% in the second quarter. Smith Asset Management Group LP now owns 5,560 shares of the company’s stock valued at $284,000 after buying an additional 5,072 shares in the last quarter.

SYNH has been the subject of several research reports. KeyCorp boosted their price target on Syneos Health from $63.00 to $65.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. UBS Group boosted their price target on Syneos Health from $53.50 to $57.00 and gave the stock a “neutral” rating in a research report on Thursday, August 29th. Credit Suisse Group boosted their price target on Syneos Health from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Friday, August 23rd. SunTrust Banks boosted their price target on Syneos Health to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research cut Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 price target for the company. in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $58.63.

Shares of SYNH traded down $0.27 during trading hours on Thursday, hitting $54.21. 15,986 shares of the stock were exchanged, compared to its average volume of 612,092. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.89 and a current ratio of 0.89. Syneos Health Inc has a 12-month low of $36.26 and a 12-month high of $56.34. The company has a market cap of $5.41 billion, a price-to-earnings ratio of 20.81, a price-to-earnings-growth ratio of 1.83 and a beta of 1.51. The stock’s 50-day moving average price is $51.06 and its two-hundred day moving average price is $48.13.

Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.61 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.02. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Syneos Health had a return on equity of 9.82% and a net margin of 0.36%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 earnings per share. On average, research analysts expect that Syneos Health Inc will post 2.73 earnings per share for the current year.

Syneos Health Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: What is diluted earnings per share (Diluted EPS)?

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.